ProQR Therapeutics N.V. Logo

ProQR Therapeutics N.V.

Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.

PRQR | US

Overview

Corporate Details

ISIN(s):
NL0010872495
LEI:
Country:
United States of America
Address:
ZERNIKEDREEF 9, LEIDEN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ProQR Therapeutics N.V. is a biotechnology company dedicated to the discovery and development of RNA therapies for severe rare and common genetic disorders. The company's core focus is its proprietary Axiomer® RNA-editing technology platform. This platform is designed to make targeted edits to RNA by recruiting the body's own ADAR (Adenosine Deaminase Acting on RNA) enzymes, representing a novel approach to treating diseases with high unmet medical needs. ProQR advances its technology through in-house research and development as well as strategic partnerships, including a major collaboration with Eli Lilly and Company to discover, develop, and commercialize new medicines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ProQR Therapeutics N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ProQR Therapeutics N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ProQR Therapeutics N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM
Inmune Bio, Inc. Logo
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America
INMB
INOVIO PHARMACEUTICALS, INC. Logo
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America
INO
Insight Molecular Diagnostics Inc. Logo
Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.
United States of America
IMDX
INSMED Inc Logo
Develops and commercializes innovative therapies for serious and rare diseases.
United States of America
INSM
Instil Bio, Inc. Logo
Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.
United States of America
TIL
Intellia Therapeutics, Inc. Logo
Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.
United States of America
NTLA
Intercure Ltd. Logo
Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.
Israel
INCR
Intervacc AB Logo
Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.
Sweden
IVACC

Talk to a Data Expert

Have a question? We'll get back to you promptly.